|
1
|
Montazeri A, Vahdaninia M, Harirchi I,
Harirchi AM, Sajadian A, Khaleghi F, Ebrahimi M and Haghighat S:
Breast cancer in Iran: Need for greater women awareness of warning
signs and effective screening methods. Asia Pac Fam Med. 7:62008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J: Cancer IAfRo: GLOBOCAN 2000:
Cancer incidence, mortality and prevalence worldwide. IARC press;
2001
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stewart B and Kleihues P: World cancer
report. Geneva: International Agency for Research on Cancer. World
Health Organization; 2003
|
|
5
|
Khatib OM and Modjtabai A: Guidelines for
the early detection and screening of breast cancer: World Health
Organization. Regional Office for the Eastern Mediterranean.
2006.
|
|
6
|
Network NCC: NCCN clinical practice
guidelines in oncology™ breast cancer: National Comprehensive
Cancer Network. 2007.
|
|
7
|
André F and Zielinski CC: Optimal
strategies for the treatment of metastatic triple-negative breast
cancer with currently approved agents. Ann Oncol. 23 suppl
6:vi46–vi51. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bauer KM and Hummon AB: Effects of the
miR-143/-145 microRNA cluster on the colon cancer proteome and
transcriptome. J Proteome Res. 11:4744–4754. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen K and Rajewsky N: The evolution of
gene regulation by transcription factors and microRNAs. Nat Rev
Genet. 8:93–103. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang TC, Yu D, Lee YS, Wentzel EA, Arking
DE, West KM, Dang CV, Thomas-Tikhonenko A and Mendell JT:
Widespread microRNA repression by Myc contributes to tumorigenesis.
Nat Genet. 40:43–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu Z, Huang X, Huang X, Zou Q and Guo Y:
The inhibitory role of Mir-29 in growth of breast cancer cells. J
Exp Clin Cancer Res. 32:982013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mott JL, Kobayashi S, Bronk SF and Gores
GJ: mir-29 regulates Mcl-1 protein expression and apoptosis.
Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang H, Zhang G, Wu JH and Jiang CP:
Diverse roles of miR-29 in cancer (review). Oncol Rep.
31:1509–1516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Letai A: Pharmacological manipulation of
Bcl-2 family members to control cell death. J Clin Invest.
115:2648–2655. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Plati J, Bucur O and Khosravi-Far R:
Dysregulation of apoptotic signaling in cancer: Molecular
mechanisms and therapeutic opportunities. J Cell Biochem.
104:1124–1149. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cimmino A, Calin GA, Fabbri M, Iorio MV,
Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et
al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:pp. 13944–13949. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bommer GT, Gerin I, Feng Y, Kaczorowski
AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al:
p53-mediated activation of miRNA34 candidate tumor-suppressor
genes. Curr Biol. 17:1298–1307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brown CJ, Lain S, Verma CS, Fersht AR and
Lane DP: Awakening guardian angels: Drugging the p53 pathway. Nat
Rev Cancer. 9:862–873. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Junttila MR and Evan GI: p53-a Jack of all
trades but master of none. Nat Rev Cancer. 9:821–829. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B,
Korzh V, Lodish HF and Lim B: MicroRNA-125b is a novel negative
regulator of p53. Genes Dev. 23:862–876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xia M, Knezevic D and Vassilev LT: p21
does not protect cancer cells from apoptosis induced by
nongenotoxic p53 activation. Oncogene. 30:346–355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Altieri DC: Survivin in apoptosis control
and cell cycle regulation in cancer. Prog Cell Cycle Res.
5:447–452. 2003.PubMed/NCBI
|
|
25
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: Key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu Y, Xu K and Yagüe E: miR-218 targets
survivin and regulates resistance to chemotherapeutics in breast
cancer. Breast Cancer Res Treat. 151:269–280. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kanwar JR, Kamalapuram SK and Kanwar RK:
Survivin signaling in clinical oncology: A multifaceted dragon. Med
Res Rev. 33:765–789. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choghaei E, Khamisipour G, Falahati M,
Naeimi B, Mossahebi-Mohammadi M, Tahmasebi R, Hasanpour M, Shamsian
S and Hashemi ZS: Knockdown of microRNA-29a changes the expression
of heat shock proteins in breast carcinoma MCF-7 cells. Oncol Res.
23:69–78. 2016. View Article : Google Scholar
|
|
30
|
Jolla L: Quantification strategies in
real-time PCR Michael W. Pfaffl. 1–112. 2004.
|
|
31
|
Yip KW and Reed JC: Bcl-2 family proteins
and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park SY, Lee JH, Ha M, Nam JW and Kim VN:
miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat
Struct Mol Biol. 16:23–29. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Michael MZ, O'Connor SM, van Holst
Pellekaan NG, Young GP and James RJ: Reduced accumulation of
specific MicroRNAs in colorectal neoplasia11note: Susan M. O'Connor
and Nicholas G. van holst pellekaan contributed equally to this
work. Mol Cancer Res. 1:882–891. 2003.PubMed/NCBI
|
|
34
|
Ha TY: MicroRNAs in human diseases: From
cancer to cardiovascular disease. Immune Netw. 11:135–454. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abbas T and Dutta A: p21 in cancer:
Intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Warfel NA and El-Deiry WS: p21WAF1 and
tumourigenesis: 20 years after. Curr Opin Oncol. 25:52–58. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Redondo M: Bcl-2, an antiapoptotic gene
indicator of good prognosis in breast cancer: The paradox. J
Carcinogene Mutagene. 4:135–139. 2013. View Article : Google Scholar
|
|
39
|
Yang J, Cao Y, Sun J and Zhang Y: Curcumin
reduces the expression of Bcl-2 by upregulating miR-15a and miR-16
in MCF-7 cells. Med Oncol. 27:1114–1118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schmidt SM, Schag K, Müller MR, Weck MM,
Appel S, Kanz L, Grünebach F and Brossart P: Survivin is a shared
tumor-associated antigen expressed in a broad variety of
malignancies and recognized by specific cytotoxic T cells. Blood.
102:571–576. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Asanuma H, Torigoe T, Kamiguchi K,
Hirohashi Y, Ohmura T, Hirata K, Sato M and Sato N: Survivin
expression is regulated by coexpression of human epidermal growth
factor receptor 2 and epidermal growth factor receptor via
phosphatidylinositol 3-kinase/AKT signaling pathway in breast
cancer cells. Cancer Res. 65:11018–11025. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jha K, Shukla M and Pandey M: Survivin
expression and targeting in breast cancer. Surg Oncol. 21:125–131.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ghanbari P, Mohseni M, Tabasinezhad M,
Yousefi B, Saei AA, Sharifi S, Rashidi MR and Samadi N: Inhibition
of survivin restores the sensitivity of breast cancer cells to
docetaxel and vinblastine. Appl Biochem Biotechnol. 174:667–681.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ofir R, Seidman R, Rabinski T, Krup M,
Yavelsky V, Weinstein Y and Wolfson M: Taxol-induced apoptosis in
human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3
and caspase-9 independent. Cell Death Differ. 9:636–642. 2002.
View Article : Google Scholar : PubMed/NCBI
|
